Description
Tirzepatide is a synthetic dual incretin research peptide that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. First synthesized as research compound LY3298176, Tirzepatide is one of the most-studied multi-receptor agonist peptides in modern metabolic research.
Tirzepatide has been extensively investigated in research models for its activity at the GIP and GLP-1 receptors and its effects on glucose homeostasis and energy balance pathways.
Research areas studied
- Glucose-dependent insulin secretion in research models
- Comparative pharmacology of dual incretin agonists
- Energy balance and lipid metabolism research
Quality assurance
- HPLC verified at 99%+ purity
- Certificate of Analysis (COA) available upon request
- Lyophilized in a research-grade facility under controlled conditions
For research purposes only. Not for human consumption, diagnostic, or therapeutic use.